How effective is Mounjaro for weight loss? What the trial data actually shows

What the SURMOUNT trials found at each dose

The SURMOUNT-1 trial randomised 2,539 adults with obesity (no diabetes) to tirzepatide at 5mg, 10mg or 15mg, or placebo, over 72 weeks. Average weight loss was around 15% at 5mg, around 19% at 10mg, and roughly 20–21% at 15mg, with some participants losing considerably more. Placebo participants lost around 3%. The size of that gap is what made the trial results notable; NICE's appraisal committee described the evidence base as robust when it recommended tirzepatide in December 2024.

A common misconception is that higher always means better, that jumping straight to the highest dose is the goal. In practice, titration starts at 2.5mg not because the lower doses are ineffective for everyone, but because the body needs time to adjust. Many people find meaningful results at 5mg or 10mg without needing to go further. Your prescriber decides the pace, not a target number.

The SURMOUNT-2 trial looked at adults with type 2 diabetes (a group where weight loss is typically harder to achieve) and still found average reductions of around 12–15% at the higher doses. These figures underline that tirzepatide's effectiveness extends beyond the specific population studied in SURMOUNT-1. For a fuller picture of how tirzepatide compares across its licensed use, the tirzepatide overview page covers the clinical programme in more detail.

How the dual-pathway mechanism drives those results

Semaglutide and liraglutide target a single hormone receptor (GLP-1). Tirzepatide targets two, GLP-1 and GIP. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to regulate energy intake, fat storage and, in some pathways, the reward signals associated with eating. Activating both appears to produce a stronger and more sustained reduction in appetite than single-agonist medicines in most people, which is the leading hypothesis for why the trial numbers are higher.

Gastric emptying also slows, which prolongs the feeling of fullness after eating. This combination (less hunger, longer satiety, improved blood-sugar control) means many people on Mounjaro find portion sizes fall naturally rather than through conscious restriction. That said, the clinical trials paired medication with a reduced-calorie diet and increased physical activity, so the medicine works best as part of a broader approach rather than in isolation. The NHS patient page on tirzepatide explains the mechanism in plain language and is worth reading before you start.

If you're curious about whether oral tirzepatide is on the horizon, there is a separate page covering how effective oral tirzepatide formulations are based on the current evidence.

How does Mounjaro compare to other weight-loss medicines?

The most direct comparison available comes from SURMOUNT-5, published in 2025 in the New England Journal of Medicine. In that open-label trial of 751 adults with obesity and no diabetes, tirzepatide produced greater average weight loss than semaglutide 2.4mg (Wegovy) over 72 weeks. It is the only published randomised head-to-head trial between the two medicines. NICE's TA1026 committee also noted that indirect comparisons across the respective trial programmes favour tirzepatide, while cautioning that cross-trial comparisons carry inherent uncertainty.

Wegovy at the newer 7.2mg dose narrows the gap, and which medicine suits a given person depends on their medical history, other medicines they take and how they respond clinically, not on a league table. The question of how Mounjaro's effectiveness holds up across different populations is explored in more depth if you want to go further into the nuances.

Cost is part of the picture too. Private treatment pricing covers the consultation, prescription, medicine and delivery as one figure, you can see current treatment options and explore what's included before speaking to a prescriber.

What affects how much weight you lose on Mounjaro?

Trial averages describe populations, not individuals. Several factors influence where any one person lands relative to those averages. The dose reached matters, people who tolerate 15mg generally lose more than those who plateau at 7.5mg. Adherence matters too; missing doses reduces the steady-state concentration of the medicine. Diet and activity during treatment are genuine contributors, not just fine print in the licence, the guidance on making Mounjaro work harder covers practical steps supported by the trial literature.

Timing within treatment is also relevant. Weight loss tends to be fastest in the first 12–20 weeks and then continues more gradually. When Mounjaro is most effective in a treatment course is a question worth understanding before starting, so expectations are grounded in the data rather than the early weeks alone.

Side effects (mainly gastrointestinal during dose increases) can disrupt adherence if not managed well. Nausea, loose stools and fatigue are most common during the titration phase and usually settle as the body adjusts. If side effects are affecting your day-to-day, what to do about Mounjaro-related fatigue covers the evidence on why it happens and what tends to help. A clinician's view on your specific situation is always the most useful starting point; our prescribers are reachable through the contact page if you have questions between orders.